DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Pivot X, Gligorov J, Müller V et al.
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Lancet Oncol 2013;
14: 962-970
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.